When picturing the various dangers faced by military members, basic training isn't the first to come to mind. But basic training facilities are the right environment--close quarters and high-stress, according to a WDBJ 7 report--for respiratory illness caused by adenovirus to thrive and spread. Enter Teva Pharmaceutical ($TEVA), which will supply military basic training camps with live, oral vaccines for adenovirus type 4 and type 7 through December 2019. The company has a 5-year contract with the Department of Defense, under which it anticipates supplying 200,000 to 250,000 doses per year, Teva spokeswoman Michelle Larkin told FierceVaccines in an email. WDBJ 7 video | Roanoke Times story